Combining options in metastatic prostate cancer

Kopp Ryan P.; Beer Tomasz M.

首页> 外文期刊>Nature reviews. Urology >Combining options in metastatic prostate cancer

【24h】

Combining options in metastatic prostate cancer

机译：组合转移前列腺癌中的选择

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

机译：强化全身疗法改善转移性前列腺癌的结果。作为奥氟胺酰胺和依甲酰胺加入AbiraTerone和Docetaxel作为患者的治疗方案，个体患者的治疗选择变得更加复杂。我们预计精确靶向和免疫疗法将在最近完成的大规模试验的进步上建立。

著录项

来源
《Nature reviews. Urology》 |2019年第10期|共2页
作者
Kopp Ryan P.; Beer Tomasz M.;
展开▼
作者单位

Oregon Hlth &

Sci Univ Dept Urol Portland OR 97201 USA;

Oregon Hlth &

Sci Univ Knight Canc Inst Portland OR 97201 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Re: Liselotte MS Boeve, Maarten CCM Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019; 75: 410-8 Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD Trial [J] . Shinde Ashwin, Li Richard, Amini Arya, European urology . 2019,第3期

机译：Re：Liselotte Ms Boeve，Maarten CCM Hulshof，Andre N. Vis等人。与雄激素剥夺治疗相比，对雄激素剥夺治疗的生存对雄激素剥夺治疗与前瞻性随机临床试验中原发性骨转移前列腺癌前列腺患者的同时剥夺治疗的影响：来自血腥审判的数据。 EUR UROL 2019; 75：410-8转移性前列腺癌中的明确治疗的未来步骤：来自血轮试验的教训
2. Combining options in metastatic prostate cancer [J] . Kopp Ryan P., Beer Tomasz M. Nature reviews. Urology . 2019,第10期

机译：组合转移前列腺癌中的选择
3. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer [J] . Benidir Tarik, Hersey Karen, Finelli Antonio, Urologic oncology . 2018,第5期

机译：了解前列腺癌患者如何重视转移性阉割抗性前列腺癌的当前治疗方案
4. Identification of Circulating Pluripotent Cancer Stem Cells in the Blood of Prostate Cancer Patients for the Diagnosis of Metastatic Cancer [C] . Anette Claudia Schafer, Yawen Ju, Youngbin Tak, International Molecular Medicine Tri-Conference. . 2016

机译：鉴定前列腺癌患者血液中循环多能癌症干细胞诊断转移性癌症
5. 3D spheroid culture systems for metastatic prostate cancer dormancy studies and anti-cancer therapeutics development. [D] . Hsiao, Amy Yu-Ching. 2011

机译：用于转移性前列腺癌休眠研究和抗癌疗法开发的3D球体培养系统。
6. Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach [O] . Kazuhiro Nagao, Hideyasu Matsuyama, Masahiro Nozawa, 2016

机译：唑来膦酸联合雄激素剥夺疗法可延长未接受过激素治疗的转移性前列腺癌患者去势抵抗性前列腺癌的时间–一种倾向性评分方法
7. Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach [O] . Kazuhiro Nagao, Hideyasu Matsuyama, Masahiro Nozawa, 2016

机译：唑来膦酸联合雄激素剥夺疗法可延长激素初治转移性前列腺癌患者去势抵抗性前列腺癌的时间 - 倾向评分方法

Combining options in metastatic prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅